Arthneeti

Elevance Health, Inc. Q2 FY26 Results — Earnings Call Analysis

Published 29 May 2026 | Health Care Providers and Services | Market Cap: ₹85.3K Cr

- Confident in at least 12% adjusted EPS growth in 2027, building from a baseline of $25.75 EPS in 2026 (Page 16). - Elevance Health expects at least 12% adjusted EPS growth in 2027 off a revised 2026 baseline of $25.75.

From Elevance Health, Inc.'s Q2 FY26 earnings-call transcript · updated 29 May 2026.

Price

₹392.75

Market Cap

₹85.3K Cr

P/E Ratio

16.4

Revenue Rank

Rank 3

Margin Rank

Rank 3

How does Elevance Health, Inc. rank in Health Care Providers and Services?

Compare Elevance Health, Inc. against every Health Care Providers and Services company this quarter on revenue, margins and earnings-call signals.

Revenue: Rank 3Margin: Rank 3
View Health Care Providers and Services leaderboard →

📊 Revenue & Sales Performance

Rank 3
  • →Confident in at least 12% adjusted EPS growth in 2027, building from a baseline of $25.75 EPS in 2026 (Page 16).
  • →Growth driven by margin expansion opportunities across most end markets and benefits from AI investments and prudent pricing strategies (Page 16).
  • →Multiple independent earnings levers in motion since 2025, including pricing, care management, and portfolio positioning (Page 16).
  • →Meaningful investments in 2026 expected to mature and boost returns in 2027 (Page 16).
  • →Strong national account sales momentum, including marquee wins and nearly 100% renewals, supported by integrated medical and pharmacy capabilities (Pages 4, 5, 9).
  • →Continued pipeline strength in employer markets and increasing consolidation of clients under single carrier arrangements (Pages 4, 9).
  • →Medicaid membership declines expected to stabilize, with margin improvement anticipated in 2027 due to better rate alignment (Pages 6, 13).
  • →AI-driven operational efficiencies and Carelon's risk-based integrated care expected to drive long-term growth (Pages 2, 16).

📈 Profitability & Margins

Rank 3
  • →Elevance Health expects at least 12% adjusted EPS growth in 2027 off a revised 2026 baseline of $25.75.
  • →This growth is driven by margin expansion across most end markets and early benefits from AI and investment spend.
  • →Key earnings levers already in motion include pricing discipline, care management, and portfolio positioning initiated in 2025 and 2026.
  • →Meaningful investments made in 2026 are expected to mature and contribute to a clear step-up in returns in 2027.
  • →The growth path relies on multiple independent levers across health benefits and Carelon, not a single assumption.
  • →For 2026, the company raised its adjusted diluted EPS guidance to at least $26.75 based on strong Q1 results.
  • →Medicaid margins are expected to remain pressured in 2026 but improve in 2027 due to better rate alignment.

🏗️ Capital Expenditure Plans

Yes
  • →Elevance Health is investing more than $1 billion in digital and AI-enabled capabilities to support their strategy of improving affordability, simplifying healthcare, and personalizing member experience.
  • →Investments are focused on embedding AI across clinical, operational, and administrative workflows to improve engagement, cost management, predictive analytics, and reduce administrative expenses through automation.
  • →Meaningful investments are being made in 2026, expected to mature and deliver returns contributing to earnings growth in 2027.
  • →Strategic investments support the scaling of Carelon’s risk-based solutions, including oncology, post-acute, and behavioral health programs.
  • →Carelon’s integrated whole health approach combines CareBridge and Care at Home into a single risk-based solution driving better outcomes and cost savings.
  • →Overall, investments are aligned with long-term durable financial performance and operational execution goals.

💰 Fundraising & Capital Structure

No information
  • →The provided transcript pages do not mention any current or planned fundraising through debt or equity.
  • →There is no discussion of issuing new shares beyond ongoing share repurchases (3.7 million shares repurchased for $1.1 billion in the quarter).
  • →Capital deployment priorities focus on share repurchases and confidence in the long-term earnings power of the business.
  • →No indication of issuing new debt or equity offerings was disclosed.
  • →The company highlights operational execution, investment in AI and digital capabilities, and disciplined financial management.
  • →No future fundraising plans via debt or equity are explicitly mentioned in this document.

📋 Order Book & Pipeline

No information
The document does not explicitly provide a detailed current or expected order book or pending orders summary. However, related insights can be inferred: - Carelon Rx reports strong sales momentum, with total sales running ahead of plan for 2026 including two marquee national account wins. - Approximately 2 million members are in the queue for national business, with some related to second blue bid opportunities. - The national account pipeline for 2027 is described as very strong, nearly at a record level, reflecting positive demand in the employer and commercial markets. - Renewals in the national business are very high, with a renewal rate of about 99.3%. - The sales strength reflects employer focus on affordability, integrated medical and pharmacy models, and differentiated Carelon Rx value. No explicit numeric order book or pending orders figure is disclosed.

Key Metrics

Revenue

Rank 3

Margin

Rank 3

Capex

Yes

Fundraise

No information

Order Book

No information

Continue your research

Others in Health Care Providers and Services this season

  • BrightSpring Health Services, Inc. (Q2 FY26)

    BrightSpring Health Services, Inc. Q2 FY26 quarterly results analysis. Pharmacy Solutions expected to see balanced sequential revenue and EBITDA growth througho

  • DaVita Inc. (Q2 FY26)

    DaVita Inc. Q2 FY26 quarterly results analysis. Treatment volume guidance raised from flat to 25-50 basis points growth for 2026, driven by better underlying pe

  • Tenet Healthcare Corporation (Q2 FY26)

    Tenet Healthcare Corporation Q2 FY26 quarterly results analysis. Hospital segment expects a 10% normalized year-over-year adjusted EBITDA growth in 2026, suppor

  • Guardant Health, Inc. (Q2 FY26)

    Guardant Health, Inc. Q2 FY26 quarterly results analysis. Sales team started this year with ~300 reps; incremental gross profit will be reinvested in expanding

Compare:vs UnitedHealth Group Incorporatedvs McKesson Corporationvs HCA Healthcare, Inc.

Frequently Asked Questions

What were Elevance Health, Inc. Q2 FY26 results?

- Confident in at least 12% adjusted EPS growth in 2027, building from a baseline of $25.75 EPS in 2026 (Page 16). - Elevance Health expects at least 12% adjusted EPS growth in 2027 off a revised 2026 baseline of $25.75.

What is Elevance Health, Inc. share price analysis?

Elevance Health, Inc. currently shows a below-average growth signal. The stock trades at a P/E of 16.4 with a market cap of $85,291. Investors should review the full earnings analysis for detailed insights.

Is Elevance Health, Inc. planning capital expenditure?

- Elevance Health is investing more than $1 billion in digital and AI-enabled capabilities to support their strategy of improving affordability, simplifying healthcare, and personalizing member experience.

Keep Elevance Health, Inc. on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.